Futuremeds Targówek
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Futuremeds Targówek, researchers are assessing new anticoagulant strategies for atrial fibrillation to reduce stroke risk.
- Evaluation of milvexian versus apixaban for cardioembolic event prevention
- Investigation of composite outcomes of stroke and systemic embolism
The work supports safer treatment options for patients with heart rhythm disorders.
Skin and Connective Tissue Diseases
The site conducts long‑term safety studies of novel oral agents for moderate‑to‑severe plaque psoriasis, aiming to improve disease control.
- Safety and tolerability of TAK‑279 in chronic skin disease
- Evaluation of treatment effectiveness over extended periods
These trials help expand therapeutic choices for individuals living with persistent skin conditions.
Bacterial Infections and Mycoses
Investigators evaluate the immunogenicity of a 21‑valent pneumococcal conjugate vaccine in children, supporting better protection against pneumococcal infection.
- Serotype‑specific IgG antibody response after vaccination
- Opsonophagocytic activity across different pediatric age groups
Futuremeds Targówek contributes to public‑health vaccination strategies for infants, toddlers, children, and adolescents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Futuremeds Targówek
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR) | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | May 2016 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2016-05-10 | 2016-05-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.